Komori
Share Issuance and Disposal4882Perseus Proteomics Inc.Pharmaceuticals

Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Adjustment Provisions

There were no exercises of the stock acquisition rights with exercise price adjustment clauses in April 2026, and no shares were delivered. As of month-end, 14,299 stock acquisition rights remained unexercised, unchanged from the end of the previous month.

Worth reading
45Recurring
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
0
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly exercise status of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数

Number of shares issued during the month: 0 shares (new shares: 0 shares; transferred treasury shares: 0 shares)

発行済株式総数

Exercise ratio during the relevant month: 0.00% (as a percentage of the total 36,800 stock acquisition rights issued)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
¥265 (as stated in the exercise status section for the relevant month; details and floor of the adjustment clause: Not disclosed)
Number of Stock Acquisition Rights
Total issued: 36,800; unexercised as of the end of the preceding month: 14,299; unexercised as of the end of the relevant month: 14,299
Procedures under the Corporate Code of Conduct
Describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financing
Stock acquisition rights with exercise price adjustment clauses issued on 5 January 2026 (29th Series Stock Acquisition Rights): Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly exercise status of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed ofNumber of shares issued during the month: 0 shares (new shares: 0 shares; transferred treasury shares: 0 shares)
Dilution RateExercise ratio during the relevant month: 0.00% (as a percentage of the total 36,800 stock acquisition rights issued)
Total number of issued shares16,999,600 shares (as of the end of the month preceding the month covered) → Not disclosed
Exercise price¥265 (as stated in the exercise status section for the relevant month; details and floor of the adjustment clause: Not disclosed)
Number of Stock Acquisition RightsTotal issued: 36,800; unexercised as of the end of the preceding month: 14,299; unexercised as of the end of the relevant month: 14,299
Procedures under the Corporate Code of ConductDescribes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financingStock acquisition rights with exercise price adjustment clauses issued on 5 January 2026 (29th Series Stock Acquisition Rights): Amount Not disclosed
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No reason stated by the company.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Adjustment Provisions | Perseus Proteomics Inc. (4882) timely disclosure | Komori